IRLAB publishes interim report for the period January – March 2025

Gothenburg, Sweden, May 7, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company’s interim report for the period January-March 2025, has been published.

IRLAB: Invitation to the interim report for Q1 2025 presentation and webcast

IRLAB publishes the Annual Report for 2024